United Therapeutics Co. (NASDAQ:UTHR) to Post Q1 2024 Earnings of $5.93 Per Share, Leerink Partnrs Forecasts

United Therapeutics Co. (NASDAQ:UTHR) – Research analysts at Leerink Partnrs boosted their Q1 2024 earnings estimates for shares of United Therapeutics in a report released on Wednesday, April 17th. Leerink Partnrs analyst R. Ruiz now anticipates that the biotechnology company will post earnings of $5.93 per share for the quarter, up from their prior estimate of $5.90. Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $23.46 per share. Leerink Partnrs also issued estimates for United Therapeutics’ Q2 2024 earnings at $6.32 EPS and Q3 2024 earnings at $7.04 EPS.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.28 by $0.08. The business had revenue of $614.70 million for the quarter, compared to the consensus estimate of $575.01 million. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The company’s quarterly revenue was up 25.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.67 EPS.

A number of other analysts also recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $300.00 target price on shares of United Therapeutics in a research report on Thursday, February 22nd. SVB Leerink initiated coverage on shares of United Therapeutics in a research report on Monday, February 5th. They issued an “outperform” rating and a $330.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and issued a $308.00 target price on shares of United Therapeutics in a research report on Thursday, February 22nd. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 11th. Finally, Wells Fargo & Company upped their price target on shares of United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a research note on Thursday, March 7th. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $292.67.

United Therapeutics Stock Up 1.5 %

NASDAQ:UTHR opened at $235.31 on Thursday. The firm’s 50-day moving average price is $230.70 and its 200-day moving average price is $228.38. The company has a market capitalization of $11.07 billion, a PE ratio of 11.86 and a beta of 0.52. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.41 and a quick ratio of 4.28. United Therapeutics has a 1-year low of $204.44 and a 1-year high of $261.54.

Insider Buying and Selling

In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $215.01, for a total transaction of $1,290,060.00. Following the transaction, the executive vice president now owns 36,599 shares in the company, valued at approximately $7,869,150.99. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $232.05, for a total transaction of $835,380.00. Following the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $30,166.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $215.01, for a total transaction of $1,290,060.00. Following the transaction, the executive vice president now owns 36,599 shares in the company, valued at approximately $7,869,150.99. The disclosure for this sale can be found here. Insiders have sold a total of 126,190 shares of company stock worth $29,672,157 in the last quarter. Corporate insiders own 12.50% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors have recently made changes to their positions in UTHR. Wellington Management Group LLP lifted its stake in shares of United Therapeutics by 73.7% in the 1st quarter. Wellington Management Group LLP now owns 1,675,414 shares of the biotechnology company’s stock worth $300,585,000 after purchasing an additional 710,668 shares during the period. Norges Bank bought a new position in shares of United Therapeutics in the 4th quarter worth approximately $100,519,000. State Street Corp lifted its stake in shares of United Therapeutics by 15.9% in the 1st quarter. State Street Corp now owns 1,795,102 shares of the biotechnology company’s stock worth $402,031,000 after purchasing an additional 245,747 shares during the period. BlackRock Inc. lifted its stake in shares of United Therapeutics by 5.4% in the 1st quarter. BlackRock Inc. now owns 4,751,961 shares of the biotechnology company’s stock worth $1,064,249,000 after purchasing an additional 241,594 shares during the period. Finally, Avidity Partners Management LP bought a new position in shares of United Therapeutics in the 4th quarter worth approximately $52,158,000. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.